CN116018352A - 一种抗IgE的工程化抗体及其应用 - Google Patents

一种抗IgE的工程化抗体及其应用 Download PDF

Info

Publication number
CN116018352A
CN116018352A CN202180049003.2A CN202180049003A CN116018352A CN 116018352 A CN116018352 A CN 116018352A CN 202180049003 A CN202180049003 A CN 202180049003A CN 116018352 A CN116018352 A CN 116018352A
Authority
CN
China
Prior art keywords
amino acid
antigen binding
binding protein
acid mutations
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049003.2A
Other languages
English (en)
Inventor
邓俗俊
顾春银
刘小五
曹晓丹
刘培培
张建建
潘忠宗
肖政
王学萍
郭海兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiyu Pharmaceutical Technology Co ltd
Jiangxi Jemincare Group Co Ltd
Original Assignee
Shanghai Jiyu Pharmaceutical Technology Co ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiyu Pharmaceutical Technology Co ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jiyu Pharmaceutical Technology Co ltd
Publication of CN116018352A publication Critical patent/CN116018352A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种抗原结合蛋白，其与奥马珠单抗的轻重链可变区序列相比，包含氨基酸突变，该抗原结合蛋白为抗IgE的工程化抗体。还涉及包含所述抗原结合蛋白的药物组合物，以及其用于缓解或治疗与异常IgE水平相关的疾病的方法。

Description

PCT国内申请，说明书已公开。

Claims (50)

  1. PCT国内申请，权利要求书已公开。
CN202180049003.2A 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用 Pending CN116018352A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020106630293 2020-07-10
CN202010663029 2020-07-10
CN202110750959 2021-07-01
CN2021107509597 2021-07-01
PCT/CN2021/105620 WO2022007965A1 (zh) 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用

Publications (1)

Publication Number Publication Date
CN116018352A true CN116018352A (zh) 2023-04-25

Family

ID=79552269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049003.2A Pending CN116018352A (zh) 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用

Country Status (11)

Country Link
US (1) US20230250191A1 (zh)
EP (1) EP4180454A1 (zh)
JP (1) JP2023541217A (zh)
KR (1) KR20230042030A (zh)
CN (1) CN116018352A (zh)
AU (1) AU2021306786A1 (zh)
BR (1) BR112023000400A2 (zh)
CA (1) CA3185192A1 (zh)
IL (1) IL299747A (zh)
TW (1) TW202214703A (zh)
WO (1) WO2022007965A1 (zh)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE233813T1 (de) 1991-08-14 2003-03-15 Genentech Inc Veränderte immunglobuline für spezifische fc- epsilon rezeptoren
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2718120A1 (en) * 2008-03-31 2009-10-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
KR20230142806A (ko) * 2018-02-09 2023-10-11 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
EP3788078A4 (en) * 2018-05-04 2022-03-02 Allakos Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA

Also Published As

Publication number Publication date
KR20230042030A (ko) 2023-03-27
AU2021306786A1 (en) 2023-02-16
TW202214703A (zh) 2022-04-16
EP4180454A1 (en) 2023-05-17
BR112023000400A2 (pt) 2023-03-21
EP4180454A9 (en) 2023-07-26
JP2023541217A (ja) 2023-09-29
US20230250191A1 (en) 2023-08-10
WO2022007965A1 (zh) 2022-01-13
IL299747A (en) 2023-03-01
CA3185192A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
WO2020043188A1 (zh) 抗cd47抗体及其应用
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
CA2883821C (en) Il-18 binding molecules
EP3010936B1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
TW200944234A (en) Humanized anti-Factor D antibodies and uses thereof
TW200836763A (en) Pegylated Aβ FAB
JP7047128B2 (ja) ヒトｉｌ－４ｒに結合する抗体、その製造方法と治療薬
KR20180089514A (ko) Tnf-알파, il-17a 및 il-17f에 대해 특이성을 갖는 다중특이적 항체 분자
TW202346343A (zh) 抗體
WO2019120060A1 (zh) 结合人il-5的单克隆抗体、其制备方法和用途
EP4095157A1 (en) Anti-angptl3 antibody and use thereof
KR20210096559A (ko) 항IL-23p19 항체 및 이의 용도
KR20230098629A (ko) 항-il5 나노 항체 및 이의 응용
TW202332692A (zh) 抗體
JP2024012394A (ja) 抗ヒトｔｌｒ７抗体
EP3683234A1 (en) Il-6r antibody and antigen binding fragment thereof and medical use
CN109776677B (zh) 一种人源化抗il-13抗体及其制备方法和应用
US20220356239A1 (en) Il-5 antibody, antigen binding fragment thereof, and medical application therefor
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
WO2022007965A1 (zh) 一种抗IgE的工程化抗体及其应用
TW202229340A (zh) 多特異性抗體及抗體組合
CN113056480A (zh) 人源化抗N截短淀粉样β单克隆抗体
WO2022063281A1 (zh) 结合人il-33的抗体、其制备方法和用途
TWI773264B (zh) 結合人ngf的抗體、其製備方法和用途
IL310427A (en) Pharmaceutical preparation of anti-R4IL antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088122

Country of ref document: HK